Margarida R G Maia

Newly approved DMD therapy Duvyzat is expected to be available to eligible adults and children in the U.S. in the third quarter of this year.

In FORTITUDE, del-brax helped adults with FSHD grow stronger muscles and reach their arms farther than they could four months earlier.

Specific mutations in the DMD gene influence how long patients retain the ability to walk, even when treated with corticosteroids, a study says.

The case is reported of a young woman who began having DMD symptoms before getting pregnant, allowing her to receive genetic counseling.

Entrada plans to initiate clinical testing of ENTR-601-44 in Duchenne MD patients amenable to exon 44 skipping later this year.